A pilot study of cdc6 as a biomarker for circulating tumor cells in patients with lung cancer.

Cheng AnGuijian LiuShi ChengBo PangShipeng SunYaying ZhangZhongdai PanXixiong Kang

Published in: Journal of clinical laboratory analysis (2020)

Cell division cycle 6 has a potential to be used as a circulating tumor cell biomarker for lung cancer. Further study in clinical application is still broad needed.

Keyphrases

circulating tumor cells
circulating tumor
single cell
cell therapy
cell free
cell proliferation
risk assessment
mesenchymal stem cells
human health